Table 4.
Comparison of postoperative functional outcomes according to prostate volume groups; <40 mL (n = 67), 40–80 mL (n = 200), and ≥80 mL (n = 131)
| Variable | Group 1 ePV <40 mL (n = 67) | Group 2 ePV 40–80 mL (n = 200) | Group 3 ePV ≥80 mL (n = 131) | P |
|---|---|---|---|---|
| IPSS total score improvement | ||||
| 1M | 4.5 (1.8-13.3) | 6.0 (−1.0–11.0) | 8.5 (6.0–14.5) | G1 vs. G2 0.685, G2 vs. G3 0.091. G1 vs. G3 0.282 |
| 3M | 8.0 (1.0–13.0) | 8.0 (3.0–14.0) | 9.0 (3.0–15.0) | G1 vs. G2 0.777, G2 vs. G3 0.701 G1 vs. G3 0.579 |
| 6M | 8.0 (1.3–12.5) | 9.0 (4.0–18.0) | 9.0 (3.0–15.0) | G1 vs. G2 0.243, G2 vs. G3 0.919 G1 vs. G3 0.301 |
| 12M | 4.0 (−2.0–11.5) | 10.0 (3.0–16.0) | 8.0 (4.0–14.5) | G1 vs. G2 0.039, G2 vs. G3 0.597 G1 vs. G3 0.115 |
| IPSS voiding subscore improvement | ||||
| 1M | 6.5 (2.5–11.3) | 5.0 (1.0–9.0) | 5.0 (3.0–12.5) | G1 vs. G2 0.359, G2 vs. G3 0.397 G1 vs. G3 0.929 |
| 3M | 6.0 (1.0–12.0) | 7.0 (2.0–10.0) | 5.5 (2.0–10.0) | G1 vs. G2 0.881, G2 vs. G3 0.933 G1 vs. G3 0.659 |
| 6M | 6.5 (2.3–9.0) | 7.0 (3.0–12.0) | 7.0 (3.0–11.0) | G1 vs. G2 0.481, G2 vs. G3 0.843 G1 vs. G3 0.508 |
| 12M | 2.0 (−1.0 – 8.5) | 6.5 (2.0–11.3) | 5.0 (2.5–10.5) | G1 vs. G2 0.060, G2 vs. G3 0.670 G1 vs. G3 0.129 |
| IPSS storage subscore improvement | ||||
| 1M | 0.5 (–3 –3.5) | 1.0 (−2.0–3.0) | 3.0 (0.3–4.0) | G1 vs. G2 0.822, G2 vs. G3 0.061 G1 vs. G3 0.171 |
| 3M | 1.0 (−2.0–4.0) | 2.0 (0.0–5.0) | 2.0 (0.0–5.0) | G1 vs. G2 0.168, G2 vs. G3 0.685 G1 vs. G3 0.092 |
| 6M | 1.0 (−1.0–6.5) | 3.0 (1.0–6.0) | 3.0 (0.0–5.0) | G1 vs. G2 0.107, G2 vs. G3 0.716 G1 vs. G3 0.369 |
| 12M | 1.0 (−1.0–4.0) | 3.0 (1.0–5.0) | 2.0 (1.0–5.0) | G1 vs. G2 0.049, G2 vs. G3 0.424 G1 vs. G3 0.188 |
| IPSS QoL score improvement | ||||
| 1M | 1.0 (0.0–2.3) | 0.0 (0.0–1.3) | 1.0 (−0.8–2.8) | G1 vs. G2 0.083, G2 vs. G3 0.440 G1 vs. G3 0.614 |
| 3M | 1.0 (0.0–3.0) | 2.0 (0.0–3.0) | 2.0 (1.0–3.0) | G1 vs. G2 0.307, G2 vs. G3 0.716 G1 vs. G3 0.146 |
| 6M | 1.0 (0.3–2.0) | 2.0 (0.5–3.0) | 2.0 (0.0–3.0) | G1 vs. G2 0.205, G2 vs. G3 0.765 G1 vs. G3 0.549 |
| 12M | 1.0 (0.0–2.0) | 2.0 (0.0–3.0) | 1.0 (0.0–3.0) | G1 vs. G2 0.066, G2 vs. G3 0.335 G1 vs. G3 0.331 |
| Qmax improvement (mL/s) | ||||
| 1M | 2.0 (−6.5–10.0) | 6.0 (−1.0–13.0) | 7.0 (1.0–16.0) | G1 vs. G2 0.050, G2 vs. G3 0.248 G1 vs. G3 0.015 |
| 3M | 8.0 (2.0–11.0) | 8.0 (1.5–17.0) | 11.0 (3.0–18.0) | G1 vs. G2 0.461, G2 vs. G3 0.232, G1 vs. G3 0.076 |
| 6M | 3.4 (−0.8–7.8) | 5.0 (−1.0–12.0) | 9.0 (6.0–13.0) | G1 vs. G2 0.343, G2 vs. G3 0.025 G1 vs. G3 0.003 |
| 12M | 3.6 (1.0–10.0) | 8.0 (1.0–14.0) | 11.0 (5.0–18.0) | G1 vs. G2 0.116, G2 vs. G3 0.125 G1 vs. G3 0.004 |
| PVR decrease (mL) | ||||
| 1M | 20.0 (0.0–75.0) | 42.5 (10.0–85.0) | 73.5 (21.3–132.5) | G1 vs. G2 0.165, G2 vs. G3 <0.001 G1 vs. G3 <0.001 |
| 3M | 31.0 (6.0–116.5) | 40.0 (10.0–102.5) | 90.0 (43.0–159.0) | G1 vs. G2 0.572, G2 vs. G3 0.005 G1 vs. G3 0.019 |
| 6M | 30.0 (−20.0–114.5) | 46.0 (9.5–104.5) | 95.0 (36.5–135.5) | G1 vs. G2 0.294, G2 vs. G3 0.048 G1 vs. G3 0.029 |
| 12M | 50.0 (5.5–99.0) | 54.0 (8.0–110.0) | 85.0 (45.0–143.0) | G1 vs. G2 0.906, G2 vs. G3 0.017 G1 vs. G3 0.066 |
ePV, estimated prostate volume; IPSS, International Prostate Symptom Score; QoL, quality of life; Qmax, maximum flow rate; PVR, post-void residual volume; VV, voided volume. Data presented are median (interquartile range). In post hoc analysis, the statistical significance was considered when the Bonferroni adjusted p value was less than 0.017.